This Issue is a relatively long one, as it’s something of a catch-up for the holiday period. We look at psychedelic drug development news from the likes of MindMed, Gilgamesh and atai as well as news stories concerning the VA and DEA. We also review and summarise our recent long-read coverage, as well as provide updates to some of those stories. Featured content in this Issue: Companies…
